Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies

Kyriakidis, Ioannis; Vasileiou, Eleni; Roilides, Emmanuel; Groll, Andreas H.; Tragiannidis, Athanasios

doi:10.3390/jof7030186

Cited by 21 publications

(28 citation statements)

References 175 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grade 3 or 4 toxicities—hypoxia, anorexia, elevated levels of blood bilirubin, GGT, and AST—were also present [ 81 ]. Other reports on InO-based therapy mentioned IFDs (invasive fungal diseases) among paediatric patients [ 82 ].…”

Section: Other Approachesmentioning

confidence: 99%

Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms

Lejman

Kuśmierczuk

Bednarz

et al. 2021

IJMS

View full text Add to dashboard Cite

Targeted therapy has revolutionized the treatment of poor-prognosis pediatric acute lymphoblastic leukemia (ALL) with specific genetic abnormalities. It is still being described as a new landmark therapeutic approach. The main purpose of the use of molecularly targeted drugs and immunotherapy in the treatment of ALL is to improve the treatment outcomes and reduce the doses of conventional chemotherapy, while maintaining the effectiveness of the therapy. Despite promising treatment results, there is limited clinical research on the effect of target cell therapy on the potential toxic events in children and adolescents. The recent development of highly specific molecular methods has led to an improvement in the identification of numerous unique expression profiles of acute lymphoblastic leukemia. The detection of specific genetic mutations determines patients’ risk groups, which allows for patient stratification and for an adjustment of the directed and personalized target therapies that are focused on particular molecular alteration. This review summarizes the knowledge concerning the toxicity of molecular-targeted drugs and immunotherapies applied in childhood ALL.

show abstract

Section: Other Approachesmentioning

confidence: 99%

Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms

Lejman

Kuśmierczuk

Bednarz

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Therapeutic approach should be considered in relation to the nature of the NBS as a DNA repair disorder, and to the remaining immune function available in the patient's body, which is required to enhance immunotherapy. Antitumoural targeted therapies, such as monoclonal antibodies (mAb), chimeric antigen receptor (CAR) T-cells and small-molecule inhibitors, potentially offer significant opportunities for optimizing treatment of lymphoid malignancies [45,46].…”

Section: Treatment Strategies Of Lymphoid Malignancies In Nbsmentioning

confidence: 99%

“…MAbs can also interfere with immune checkpoint pathways and allow potentiate anti-tumour responses, for instance, pembrolizumab -antiprogrammed cell-death 1 -PD1. The CAR T-cells, which are autologous T-cells from patients and genetically engineered to express tumor-reactive CARs, are the most recent method of treatment [46,47]. The next group are inhibitors of PI3K/ AKT/mTOR pathway, such as sirolimus.…”

Section: Treatment Strategies Of Lymphoid Malignancies In Nbsmentioning

confidence: 99%

Diagnostic and therapeutic approach to children with Nijmegen breakage syndrome in relation to development of lymphoid malignancies

Filipiuk¹,

Kozakiewicz²,

Kośmider³

et al. 2021

Ann Agric Environ Med.

View full text Add to dashboard Cite

“…Paediatric haematology-oncology patients constitute a considerable part of this population [ 8 , 9 ]. On the one hand, they suffer from a disease that, by nature, impairs their immunity, and on the other hand they receive immunosuppressive treatments that further diminish their ability to properly respond to infection [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Capacity for Invasive Fungal Infections in the Greek Paediatric Haematology-Oncology Units: Report from the Infection Working Group of the Hellenic Society of Paediatric Haematology-Oncology

Markantonatou

Tragiannidis

Galani

et al. 2021

JoF

Self Cite

View full text Add to dashboard Cite

An audit based on a specific questionnaire was attempted, in order to investigate the mycology laboratory diagnostic capacity for invasive fungal diseases (IFDs) in Greek Paediatric Haematology-Oncology departments/units. The study provided the relevant information for the years 2019 and 2020 and included data from all units, concerning culture-based methods and direct microscopy, phenotypic and molecular identification, sensitivity testing, serology and molecular diagnosis, as well as therapeutic drug monitoring. The target was mostly to reveal the level of laboratory coverage for hospitalised paediatric patients, independently of the possibility of performing the tests in the host hospital, or otherwise to refer the specimens elsewhere. In total, the current study demonstrated that the most important facilities and services regarding the IFD diagnostics for paediatric haematology-oncology patients in Greece are available and relatively easily accessible, with a reasonable turnaround time. Acting as an initial registry for further improvements, the audit can serve as a valuable approach to the actual situation and future perspectives. A national clinical mycology network under the auspices of the relevant scientific societies will probably facilitate collaboration between all the departments (clinical and laboratory) involved in invasive fungal infections and provide an easier approach to any necessary test for any hospitalised patient.

show abstract

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies

Cited by 21 publications

References 175 publications

Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms

Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms

Diagnostic and therapeutic approach to children with Nijmegen breakage syndrome in relation to development of lymphoid malignancies

Diagnostic Capacity for Invasive Fungal Infections in the Greek Paediatric Haematology-Oncology Units: Report from the Infection Working Group of the Hellenic Society of Paediatric Haematology-Oncology

Contact Info

Product

Resources

About